Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors

NCT05263050 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

111

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Renal Cell Carcinoma
Clear-cell Metastatic Renal Cell Carcinoma
Neuroendocrine Tumors
Carcinoid Tumor

Interventions

DRUG: Cabozantinib
DRUG: Nivolumab

Sponsor

Fox Chase Cancer Center

Collaborators

[object Object]